HSP90B2P and lymphoma: In this study, we confirmed the efficacy of HSP70 and HSP90 inhibition as a promising therapeutic option against this aggressive lymphoma associated to the oncovirus KSHV, and unveiled new molecular mechanisms leading to the cytotoxicity induced by these HSP inhibitors.